Ahahaha. Someone posted: http://i31.tinypic.com/2rnkdoh.jpg , in the database error thread as the error that showed up to them when accessing the forums.
Subtle.
Yeah I figure Bama, just seems like public humilation you could avoid. I mean its one thing when someone else tapes it.
Preacher on
I would like some money because these are artisanal nuggets of wisdom philistine.
Ahahaha. Someone posted: http://i31.tinypic.com/2rnkdoh.jpg , in the database error thread as the error that showed up to them when accessing the forums.
So this is practically the last thing i need to do for this shitter of a assignment. Sorry I am dumping this here, but i need to know if this is even readable. Fuck man, i joined biotech to do bio, and tech, not fucking business!
To analyze the potential profitability of AMLout™ a thorough economic analysis must be performed. This must factor in the costs of research, production and commercialization with a number of varying parameters, which will allow identification of key areas that influence profit. All costings for R&D, capital, operation, marketing, royalities, regulatory fees and other expenses have been summarized in Appendices 2-7, 2-9, 3-1, 3-2, 4-2, 5-2 & 6-1
A satisfactory negotiated licensing agreement between our research group and the purchasing company would consist of a minimum Lump Sum Payment of $50,000,000 coupled with royalties equaling 3% of all sales revenue when AMLout™ is released on the market. This will provide for the 6 years of research, covering building & staff costs. Production costs will be mostly handled by the purchasing company, and as such, do not appear in the IRR reports that cater to the perspective of the research group, other than those incurred by the requirements of Clinical Trials. However, in the reports created for the perspective of a purchasing company, production represents a major costing obstacle, and is highly dependent on the projected annual market demand for the product. This is estimated to increase as the market size expands, at approximately 5% per annum. However, several of the case studies investigate the possibilities of greatly reduced production costs, which is possible given the size and production capabilities of the purchasing company in question. Marketing expenditure has be set at 8% of total sales revenue, and is only of concern to the purchasing pharmaceutical firm. See Appendix 6-1.
The anticipated market size of AMLout™ has been used to estimate sales revenue, and with the introductory 10% market share growing at 5% per year till a peak of 45%, this results in a peak revenue of $3,395,107 ($2,172,869 after tax) in the year 2028.
The IRR of the base case scenario sits at 19.1% This IRR value presents a low level of return over the life of the project, indicating the potential of AMLout™ as a profitable business venture is questionable. The criteria of this base case is outlined below.
1. AMLout™ is priced at $200,000 per treatment
2. During years of positive cash flow, a 36% business tax is applicable
3. R&D will take 11 years from start to finish, of which we will complete the first 6 years in our facility.
4. Production costs of AMLout™ are based on the required amount of AMLout™ for Pre-Clinical, Phase I and Phase IIa Clinical Trials. After this point, production costs are the domain of the purchasing company.
5. The increase in market growth will be reflected in an increase in sales revenue (5% per annum)
6. Royalties for rights to use patented technology has been negotiated to be 1.5% sales revenue per patent holder. The purchasing company will be responsible to pay these for the remainder of the life of the patents, in addition to a 3% royalty on sales revenue for the license of AMLout™
7. Licensee will pay for both IP costs and patent maintenance fees.
These criteria were then altered to perform sensitivity analysis, exploring the effects of these changes. Alterations in cash flow and projections of economic viability were also other scenarios that were investigated via sensitivity analysis. The resulting IRRs from these analyses have been compiled in the table below.
So, do the words line up in a recognisable order? I have been trying to proof it my self, but by the time I reach the end of once sentence, i have forgotton what was at the start. Sooooo tired!
Ahahaha. Someone posted: http://i31.tinypic.com/2rnkdoh.jpg , in the database error thread as the error that showed up to them when accessing the forums.
Ahahaha. Someone posted: http://i31.tinypic.com/2rnkdoh.jpg , in the database error thread as the error that showed up to them when accessing the forums.
Ahahaha. Someone posted: http://i31.tinypic.com/2rnkdoh.jpg , in the database error thread as the error that showed up to them when accessing the forums.
What is it?
I haz a work filter.
oddly enough it is a picture of my enormous wang.
I wish to see this ginormo-penis.
people complain about my pictures so its about like this:
Podlyyou unzipped me! it's all coming back! i don't like it!Registered Userregular
edited August 2009
So today is the first day off from work that I've had in 15 days and the first day off from work or music in about a month. I feel like a battered housewife.
Ahahaha. Someone posted: http://i31.tinypic.com/2rnkdoh.jpg , in the database error thread as the error that showed up to them when accessing the forums.
What is it?
I haz a work filter.
oddly enough it is a picture of my enormous wang.
I wish to see this ginormo-penis.
people complain about my pictures so its about like this:
Ahahaha. Someone posted: http://i31.tinypic.com/2rnkdoh.jpg , in the database error thread as the error that showed up to them when accessing the forums.
What is it?
I haz a work filter.
oddly enough it is a picture of my enormous wang.
I wish to see this ginormo-penis.
people complain about my pictures so its about like this:
Is there some way to make Linux (let's say I don't know...ubuntu) mimic the behavior of remote desktop on windows i.e. when you login it connects you to the running session but asks for authentication before it does?
So this is practically the last thing i need to do for this shitter of a assignment. Sorry I am dumping this here, but i need to know if this is even readable. Fuck man, i joined biotech to do bio, and tech, not fucking business!
To analyze the potential profitability of AMLout™ a thorough economic analysis must be performed. This must factor in the costs of research, production and commercialization with a number of varying parameters, which will allow identification of key areas that influence profit. All costings for R&D, capital, operation, marketing, royalities, regulatory fees and other expenses have been summarized in Appendices 2-7, 2-9, 3-1, 3-2, 4-2, 5-2 & 6-1
A satisfactory negotiated licensing agreement between our research group and the purchasing company would consist of a minimum Lump Sum Payment of $50,000,000 coupled with royalties equaling 3% of all sales revenue when AMLout™ is released on the market. This will provide for the 6 years of research, covering building & staff costs. Production costs will be mostly handled by the purchasing company, and as such, do not appear in the IRR reports that cater to the perspective of the research group, other than those incurred by the requirements of Clinical Trials. However, in the reports created for the perspective of a purchasing company, production represents a major costing obstacle, and is highly dependent on the projected annual market demand for the product. This is estimated to increase as the market size expands, at approximately 5% per annum. However, several of the case studies investigate the possibilities of greatly reduced production costs, which is possible given the size and production capabilities of the purchasing company in question. Marketing expenditure has be set at 8% of total sales revenue, and is only of concern to the purchasing pharmaceutical firm. See Appendix 6-1.
The anticipated market size of AMLout™ has been used to estimate sales revenue, and with the introductory 10% market share growing at 5% per year till a peak of 45%, this results in a peak revenue of $3,395,107 ($2,172,869 after tax) in the year 2028.
The IRR of the base case scenario sits at 19.1% This IRR value presents a low level of return over the life of the project, indicating the potential of AMLout™ as a profitable business venture is questionable. The criteria of this base case is outlined below.
1. AMLout™ is priced at $200,000 per treatment
2. During years of positive cash flow, a 36% business tax is applicable
3. R&D will take 11 years from start to finish, of which we will complete the first 6 years in our facility.
4. Production costs of AMLout™ are based on the required amount of AMLout™ for Pre-Clinical, Phase I and Phase IIa Clinical Trials. After this point, production costs are the domain of the purchasing company.
5. The increase in market growth will be reflected in an increase in sales revenue (5% per annum)
6. Royalties for rights to use patented technology has been negotiated to be 1.5% sales revenue per patent holder. The purchasing company will be responsible to pay these for the remainder of the life of the patents, in addition to a 3% royalty on sales revenue for the license of AMLout™
7. Licensee will pay for both IP costs and patent maintenance fees.
These criteria were then altered to perform sensitivity analysis, exploring the effects of these changes. Alterations in cash flow and projections of economic viability were also other scenarios that were investigated via sensitivity analysis. The resulting IRRs from these analyses have been compiled in the table below.
So, do the words line up in a recognisable order? I have been trying to proof it my self, but by the time I reach the end of once sentence, i have forgotton what was at the start. Sooooo tired!
ughh. I can't read this business crap. More charts, Less words.
I have also like, 80 excell spreadsheets of number crunching that have been condensed into this wall of text. I have no idea how to even put them into the main document for printing!
Oh great a whole thread dedicated to breeders. Well I guess it was only natural after we had one about not breeding you damn breeders had to go and do a "the condom broke lol" thread.
Preacher on
I would like some money because these are artisanal nuggets of wisdom philistine.
ughh. I can't read this business crap. More charts, Less words.
I have also like, 80 excell spreadsheets of number crunching that have been condensed into this wall of text. I have no idea how to even put them into the main document for printing!
An adobe binder would do this nicely. If not, I always found it miserable embedding asstons of charts into a word doc so I'm sure there is a better way. I personally have found that better way to be adobe...
I jut found a picture of me from college. A little heavier, with really long, almost girly hair. Christ. I was a total puffer! No idea how I got laid (by women).
Posts
Subtle.
Yeah I figure Bama, just seems like public humilation you could avoid. I mean its one thing when someone else tapes it.
pleasepaypreacher.net
DUE you best keep a girl focused in your ava
because I can't be the only one with a pretty ava/sig
I just can't
oddly enough it is a picture of my enormous wang.
I'd be more suspicious of the idea that he destroyed the wall behind the monitor before filming.
To analyze the potential profitability of AMLout™ a thorough economic analysis must be performed. This must factor in the costs of research, production and commercialization with a number of varying parameters, which will allow identification of key areas that influence profit. All costings for R&D, capital, operation, marketing, royalities, regulatory fees and other expenses have been summarized in Appendices 2-7, 2-9, 3-1, 3-2, 4-2, 5-2 & 6-1
A satisfactory negotiated licensing agreement between our research group and the purchasing company would consist of a minimum Lump Sum Payment of $50,000,000 coupled with royalties equaling 3% of all sales revenue when AMLout™ is released on the market. This will provide for the 6 years of research, covering building & staff costs. Production costs will be mostly handled by the purchasing company, and as such, do not appear in the IRR reports that cater to the perspective of the research group, other than those incurred by the requirements of Clinical Trials. However, in the reports created for the perspective of a purchasing company, production represents a major costing obstacle, and is highly dependent on the projected annual market demand for the product. This is estimated to increase as the market size expands, at approximately 5% per annum. However, several of the case studies investigate the possibilities of greatly reduced production costs, which is possible given the size and production capabilities of the purchasing company in question. Marketing expenditure has be set at 8% of total sales revenue, and is only of concern to the purchasing pharmaceutical firm. See Appendix 6-1.
The anticipated market size of AMLout™ has been used to estimate sales revenue, and with the introductory 10% market share growing at 5% per year till a peak of 45%, this results in a peak revenue of $3,395,107 ($2,172,869 after tax) in the year 2028.
The IRR of the base case scenario sits at 19.1% This IRR value presents a low level of return over the life of the project, indicating the potential of AMLout™ as a profitable business venture is questionable. The criteria of this base case is outlined below.
1. AMLout™ is priced at $200,000 per treatment
2. During years of positive cash flow, a 36% business tax is applicable
3. R&D will take 11 years from start to finish, of which we will complete the first 6 years in our facility.
4. Production costs of AMLout™ are based on the required amount of AMLout™ for Pre-Clinical, Phase I and Phase IIa Clinical Trials. After this point, production costs are the domain of the purchasing company.
5. The increase in market growth will be reflected in an increase in sales revenue (5% per annum)
6. Royalties for rights to use patented technology has been negotiated to be 1.5% sales revenue per patent holder. The purchasing company will be responsible to pay these for the remainder of the life of the patents, in addition to a 3% royalty on sales revenue for the license of AMLout™
7. Licensee will pay for both IP costs and patent maintenance fees.
These criteria were then altered to perform sensitivity analysis, exploring the effects of these changes. Alterations in cash flow and projections of economic viability were also other scenarios that were investigated via sensitivity analysis. The resulting IRRs from these analyses have been compiled in the table below.
So, do the words line up in a recognisable order? I have been trying to proof it my self, but by the time I reach the end of once sentence, i have forgotton what was at the start. Sooooo tired!
Look you can't just make shit up, you aren't quentin tarantino!
pleasepaypreacher.net
Currently DMing: None
Characters
[5e] Dural Melairkyn - AC 18 | HP 40 | Melee +5/1d8+3 | Spell +4/DC 12
I wish to see this ginormo-penis.
Only some of them do, as the rest are typical americans and only speak english.
pleasepaypreacher.net
Full size below
gosh
well just about everything come to think of it.
8=======D
*
*balls not to scale
I dread the dub. Dread! But oddly enough it's just playing in one OV cinema (and that one's pretty shitty).
Well we all know you at least like achewood.
pleasepaypreacher.net
Yeah seeing a dub of it would be terrible, if only because you'd miss out on Pitts hilarious accent.
pleasepaypreacher.net
Lexington Steele is not impressed.
sorry. fixed.
thats not what he told me.
ughh. I can't read this business crap. More charts, Less words.
pleasepaypreacher.net
so they all just go away
i don't want them to die, or anything
i just want them to stop killing my hobby
I have also like, 80 excell spreadsheets of number crunching that have been condensed into this wall of text. I have no idea how to even put them into the main document for printing!
pleasepaypreacher.net
What did they do?
pleasepaypreacher.net
Yeah, something did. I found out you could crl-c, paste special ---> transpose. Saved me hours of work.
your hobby is raping indie girls?
What do you work for blizzards new content development team or something?
And christ someone make sure joshua1 doesn't get the new thread.
pleasepaypreacher.net
You, of course, realize this is practically your version of fried chicken and watermelon right?
An adobe binder would do this nicely. If not, I always found it miserable embedding asstons of charts into a word doc so I'm sure there is a better way. I personally have found that better way to be adobe...
More like a side project of his real hobby, which is raping women into loving him.
pleasepaypreacher.net
Sometimes you just have to realize, fried chicken is tasty, as are babies.
pleasepaypreacher.net
what's up, mariposa?